天坛生物：2025年半年度净利润约6.33亿元，同比下降12.88%

Core Viewpoint - TianTan Biological (SH 600161) reported a year-on-year increase in revenue for the first half of 2025, but a decline in net profit and earnings per share [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 3.11 billion yuan, representing a year-on-year increase of 9.47% [2] - The net profit attributable to shareholders of the listed company was approximately 633 million yuan, showing a year-on-year decrease of 12.88% [2] - Basic earnings per share were 0.32 yuan, which also decreased by 12.88% year-on-year [2]